Real‐World Pediatric Blinatumomab Administration: Access to Outpatient Care Delivery and Impact of a Hospital‐Dispensed Model
Blinatumomab has been shown to be highly effective for patients with pediatric B-ALL and has recently become standard of care therapy. Due to its past use in the clinical trial setting, there is limited information available about real-world administration. In this brief report, we describe our institutional experience administering blinatumomab during the first year as standard of care therapy, including initial challenges in providing access to patients without home health coverage. We describe our process for developing and implementing a process for hospital-dispensed blinatumomab, which reduced access barriers for patients.
Authors
- Anne F. Reilly (ORCID: https://orcid.org/0000-0002-0523-7600)
- Stephen P. Hunger (ORCID: https://orcid.org/0000-0002-5492-3957)
- Susan R. Rheingold (ORCID: https://orcid.org/0000-0001-8025-6767)
- Kelly A. Duffy (ORCID: https://orcid.org/0000-0001-8902-8453)
- Haley Newman (ORCID: https://orcid.org/0000-0002-3022-8052)
- Allison Barz Leahy (ORCID: https://orcid.org/0000-0002-1368-4064)
- Katelyn Oranges
- J.-P. Lee
- Sara McDonough
- Daniel J. Zheng
- David T. Teachey
- R. Jennifer Randall
- Evelyn Kurpiewski
Institutions
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2026-04-10
- DOI
- https://doi.org/10.1002/1545-5017.70314
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute